Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 19/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22678941 | 0.88 | CCR4 (0.66) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL18803 | 0.86 | CCR4 (0.54) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL30084 | 0.83 | CCR4 (0.53) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL185508 | 0.82 | CCR4 (0.60) | CCR4 | |
| SCHEMBL18001 | 0.82 | CCR4 (0.56) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL27431 | 0.82 | CCR4 (0.47) | CCR4 | |
| SCHEMBL12473980 | 0.81 | CCR4 (0.48) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL29977 | 0.80 | CCR4 (0.72) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL29814 | 0.79 | CCR4 (0.71) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL29953 | 0.79 | CCR4 (0.71) | CCR4CCR5FFAR4SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8357716-B2 | Pyrazole derivatives used as CCR4 receptor antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357716-B2 | Pyrazole derivatives used as CCR4 receptor antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357716-B2 | Pyrazole derivatives used as CCR4 receptor antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8304446-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| WO-2012025473-A1 | CC.CHEMOKINE RECEPTOR 4 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025473-A1 | CC.CHEMOKINE RECEPTOR 4 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | CCR4 1/4885MTNR1A 1897/4885MTNR1B 1303/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | CCR4 3196/4885MTNR1A 3331/4885MTNR1B 2244/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | CCR4 3196/4885MTNR1A 3331/4885MTNR1B 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.